Serological responses to the first four doses of SARS-CoV-2 vaccine in patients with inflammatory bowel disease

Quan, Joshua; Ma, Christopher; Panaccione, Remo; Hracs, Lindsay; Sharifi, Nasibeh; Herauf, Michelle; Markovinovic, Ante; Coward, Stephanie; Windsor, Joseph W.; Caplan, Léa; Ingram, Richard J M; Charlton, Carmen; Kanji, Jamil N; Holodinsky, Jessalyn K.; Bernstein, Çharles N.; Mahoney, Douglas J.; Bernatsky, Sasha; Benchimol, Eric I.; Kaplan, Gilaad G.

doi:10.1016/s2468-1253(22)00340-5

Cited by 9 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Participants with IBD were enrolled into a prospective cohort study of serological responses to SARS-CoV-2 vaccines in Calgary, Alberta (4)(5)(6). Participants were interviewed by trained research coordinators using the Adverse Events Following Immunization (AEFI) form, designed to capture any adverse events within 30 days of the first, second, third, and/or fourth dose of a monovalent mRNA SARS-CoV-2 vaccine (7).…”

Section: Methodsmentioning

confidence: 99%

“…Serum samples were collected 1-12 weeks after each vaccine dose. The Abbott Architect assay series measured anti-SARS-CoV-2 nucleocapsid antibodies of SARS-CoV-2 (anti-N) to determine natural infection and anti-SARS-CoV-2 spike protein antibodies (anti-S) to quantify serological response to vaccination (5)(6)(7). Age, sex, IBD type, vaccine type and date, prior coronavirus disease 2019 diagnoses, and IBD medication status at each vaccine dose were chart reviewed.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Adverse Events and Serological Responses After SARS-CoV-2 Vaccination in Individuals With Inflammatory Bowel Disease

et al. 2023

Self Cite

View full text Add to dashboard Cite

We determined adverse events after 4 doses of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine in those with inflammatory bowel disease (IBD), associations between antibodies and injection site reactions (ISR), and risk of IBD flare. METHODS:Individuals with IBD were interviewed for adverse events to SARS-CoV-2 vaccine. Multivariable linear regression assessed the association between antibody titers and ISR. RESULTS:Severe adverse events occurred in 0.03%. ISR were significantly associated with antibody levels after the fourth dose (geometric mean ratio 5 2.56; 95% confidence interval 1.18-5.57). No cases of IBD flare occurred. DISCUSSION:SARS-CoV-2 vaccines are safe for those with IBD. ISR after the fourth dose may indicate increased antibodies.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Adverse Events and Serological Responses After SARS-CoV-2 Vaccination in Individuals With Inflammatory Bowel Disease

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Leitlinie – Kapitel 5: Impfungenunclassified

“…Daher sollte unter Verwendung dieser Therapien die Durchführung einer Auffrischimpfung erwogen werden. Sofern die letzte bekannte Antigenexposition bereits mindestens 12 Monate zurückliegt, soll die Auffrischimpfung vorzugsweise im Herbst verabreicht werden[43,97]. Sie kann mit der für alle CED Patienten (Kinder und Erwachsenen) empfohlenen Influenza-Impfung kombiniert werden.Pädiatrische Patienten: Während das RKI wegen überwiegend milder Krankheitsverläufe bei Säuglingen, (Klein-)Kindern und Jugendlichen ohne Grundkrankheiten keine SARS-CoV-2-Grundimmunisierung oder regelmäßige Auffrischimpfung empfiehlt, besteht die Empfehlung zur Impfung für Patienten ab einem Alter von 6 Monaten bei einer Grundkrankheit mit erhöhtem Risiko für eine schweren COVID-19-Verlauf[43].…”

unclassified

Update des Addendums zu den S3-Leitlinien Morbus Crohn und Colitis ulcerosa: Betreuung von Patienten mit chronisch-entzündlichen Darmerkrankungen in Bezug auf COVID-19 (Version 2.0)

Schmidt,

Stallmach,

Sturm

et al. 2024

Z Gastroenterol

View full text Add to dashboard Cite

“…Previous research showed that fourth dose vaccination with bivalent omicron-adapted mRNA vaccines potently increases breadth of virus neutralisation and improves BQ.1.1 neutralisation in haemodialysis patients with impaired virus neutralisation after three vaccine doses 50,51. Furthermore, the STOP COVID-19 in IBD study reported an increase of anti-spike IgG concentrations in patients with IBD vaccinated with a fourth dose of BNT-162b2 or mRNA-1273 52. Despite recommendations of fourth dose vaccination in immunosuppressed patients with IBD, only four out of 146 participants received a fourth vaccine dose by the end of the study, which highlights the urge of continued vaccination campaigns.…”

mentioning

confidence: 99%

STAR SIGN study: Evaluation of COVID‐19 vaccine efficacy against the SARS‐CoV‐2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease

Woelfel

Dütschler

König

et al. 2023

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SummaryBackgroundVaccine‐elicited immune responses are impaired in patients with inflammatory bowel disease (IBD) treated with anti‐TNF biologics.AimsTo assess vaccination efficacy against the novel omicron sublineages BQ.1.1 and XBB.1.5 in immunosuppressed patients with IBD.MethodsThis prospective multicentre case–control study included 98 biologic‐treated patients with IBD and 48 healthy controls. Anti‐spike IgG concentrations and surrogate neutralisation against SARS‐CoV‐2 wild‐type, BA.1, BA.5, BQ.1.1, and XBB.1.5 were measured at two different time points (2–16 weeks and 22–40 weeks) following third dose vaccination. Surrogate neutralisation was based on antibody‐mediated blockage of ACE2‐spike protein–protein interaction. Primary outcome was surrogate neutralisation against tested SARS‐CoV‐2 sublineages. Secondary outcomes were proportions of participants with insufficient surrogate neutralisation, impact of breakthrough infection, and correlation of surrogate neutralisation with anti‐spike IgG concentration.ResultsSurrogate neutralisation against all tested sublineages was reduced in patients with IBD who were treated with anti‐TNF biologics compared to patients treated with non‐anti‐TNF biologics and healthy controls (each p ≤ 0.001) at visit 1. Anti‐TNF therapy (odds ratio 0.29 [95% CI 0.19–0.46]) and time since vaccination (0.85 [0.72–1.00]) were associated with low, and mRNA‐1273 vaccination (1.86 [1.12–3.08]) with high wild‐type surrogate neutralisation in a β‐regression model. Accordingly, higher proportions of patients treated with anti‐TNF biologics had insufficient surrogate neutralisation against omicron sublineages at visit 1 compared to patients treated with non‐anti‐TNF biologics and healthy controls (each p ≤ 0.015). Surrogate neutralisation against all tested sublineages decreased over time but was increased by breakthrough infection. Anti‐spike IgG concentrations correlated with surrogate neutralisation.ConclusionsPatients with IBD who are treated with anti‐TNF biologics show impaired neutralisation against novel omicron sublineages BQ.1.1 and XBB.1.5 and may benefit from prioritisation for future variant‐adapted vaccines.

show abstract

Serological responses to the first four doses of SARS-CoV-2 vaccine in patients with inflammatory bowel disease

Cited by 9 publications

References 11 publications

Adverse Events and Serological Responses After SARS-CoV-2 Vaccination in Individuals With Inflammatory Bowel Disease

Adverse Events and Serological Responses After SARS-CoV-2 Vaccination in Individuals With Inflammatory Bowel Disease

Update des Addendums zu den S3-Leitlinien Morbus Crohn und Colitis ulcerosa: Betreuung von Patienten mit chronisch-entzündlichen Darmerkrankungen in Bezug auf COVID-19 (Version 2.0)

STAR SIGN study: Evaluation of COVID‐19 vaccine efficacy against the SARS‐CoV‐2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease

Contact Info

Product

Resources

About